United Therapeutics is trading at $585.27, up 8.38% versus the October 14 close of $540.03, with no verified overnight announcement or report clearly explaining the pre-market rise.
- The Liquidia settlement was announced October 13; Reuters reported United Therapeutics shares fell 0.46% on October 14, so the settlement does not clearly account for this later move.
- The supplied market context is mixed and does not show a broad same-direction rally that explains the gain.